Skip to content

MaxCyte MXCT Change in Inventories

Change in Inventories at other companies

Rapid Micro Biosystems logo
Rapid Micro BiosystemsRPID
-$144K-113%
PDE
Pro-Dex, Inc.PDEX
-$228K-106%
Repligen logo
RepligenRGEN
$12.07M+215%
TEC
Bio-TechneTECH
$1.94M-78.2%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$9.6M-5.0%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$845K+325%

Other financials

Income statement

See full
Revenue$9.7M-7.1%
Gross profit$8.1M-9.1%
Operating income-$6.2M+49.7%
Net income-$4.8M+53.7%
EPS (diluted)-$0.04+60.0%

Balance sheet

See full
Cash & equivalents$14.6M-37.8%
Total debt$17.5M-7.1%
Total equity$167.9M-15.8%
Total assets$194.5M-15.4%

Cash flow

See full
Operating cash flow-$8.2M+43.3%
CapEx$72.0K-89.0%
Free cash flow-$8.2M+45.3%

Valuation

See full
Market cap$130.15M-46.8%
Enterprise value$133.08M-46.3%
P/S-2.8×

Profitability

See full
Gross margin80.5%-0.4pp
Operating margin-141.8%+6.4pp
Net margin-121.2%+12.3pp
FCF margin-90.9%+3.7pp

Returns & leverage

See full
Return on equity-21.3%+2.0pp
Debt / equity0.1×0.0×
Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's change in inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MaxCyte's change in inventories?
MaxCyte (MXCT) reported change in inventories of $380K in Q1 2026.
How has MaxCyte's change in inventories changed year-over-year?
MaxCyte's change in inventories increased by 171.6% year-over-year, from -$531K to $380K.
What is the long-term trend for MaxCyte's change in inventories?
Over 3 years (2021 to 2024), MaxCyte's change in inventories has grown at a -3.4% compound annual growth rate (CAGR), from $1.51M to -$1.36M.
What does change in inventories mean?
Increase or decrease in inventory levels, directly affecting operating cash flow and working capital.